Back to search

Japan· JP-1149013F1091

ジメトチアジンメシル酸塩

A dimetotiazine product containing ジメトチアジンメシル酸塩, registered in Japan by 共和薬品工業, on the national reimbursement list.

On Japan’s NHI price listATC N02CX05

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedジメトチアジンメシル酸塩ATCN02CX05REGISTER NO.JP-1149013F1091PACKS LISTED0CHECKEDSeptember 25, 2026

The record

At a glance

MHLW / PMDA (Japan)
Active substance
ジメトチアジンメシル酸塩
Manufacturer
共和薬品工業
Country
Japan (JP)
ATC code
N02CX05
ATC class
Dimetotiazine
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b98d24a9-45b7-4763-9f78-af662a890155
GET /v1/drugs/b98d24a9-45b7-4763-9f78-af662a890155?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "20mg1錠",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "1149013F1091",
  "category": "内用薬",
  "price_yen": 8.2,
  "generic_name": "ジメトチアジンメシル酸塩",
  "product_name_jp": null,
  "therapeutic_class": "1149",
  "transitional_expiry": null
}

See everything about dimetotiazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.